FTUS
TPST icon

Flow Traders U.S.’s Tempest Therapeutics TPST Stock Holding History

Flow Traders U.S.’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-6
Closed -$150K – 224
2013
Q4 		$150K Sell
6
-3
-33% -$82.3K 0.02% 114
2013
Q3 		$257K Sell
9
-3
-25% -$106K 0.04% 105
2013
Q2 		$489K Buy
+12
New +$451K 0.15% 50

Other funds holding TPST

DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Flow Traders U.S.'s TPST Position: Q1 2014 in Review

Flow Traders U.S. sold out of Tempest Therapeutics (TPST) in Q1 2014, closing a stake of 6 shares — an estimated $150K sold.

Flow Traders U.S. first reported a position in TPST in Q2 2013 and held it in 3 quarters. The position peaked at $489K in Q2 2013. 45 funds tracked by Wall St. Rank hold TPST as of Q1 2014.

  • Flow Traders U.S. reported no remaining Tempest Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Flow Traders U.S. sold 6 Tempest Therapeutics shares in Q1 2014, an estimated $150K.
  • Flow Traders U.S. first reported a position in Tempest Therapeutics in Q2 2013 and held it in 3 quarters.
  • Flow Traders U.S.'s Tempest Therapeutics position peaked at $489K in Q2 2013.
  • 45 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2014.

Based on Flow Traders U.S.'s 13F filing for Q1 2014, filed 14 May 2014.